One third of TrumpRx drugs cost more than UK, Farxiga up to 82% pricier
One third of the 54 drugs on Trump's TrumpRx website are listed at higher prices than UK NHS payouts, including AstraZeneca's Farxiga, which is priced up to 82% below US levels in Britain. The program launched in January under most-favored-nation deals but acts only as a cash-price ceiling.
1. Pricing Comparison
TrumpRx lists 54 prescription medicines with most-favored-nation pricing, but roughly one third of these are priced higher than UK NHS payouts. The disparity highlights a gap between intended US cost reductions and actual list prices compared to British government rates.
2. Impact on AstraZeneca's Farxiga
AstraZeneca’s Farxiga, a leading diabetes medication, is up to 82% cheaper under UK NHS reimbursements than the price listed on TrumpRx. This significant differential may influence patient access and US market competitiveness for the drug.
3. Program Mechanics and Limitations
Launched in January, the TrumpRx initiative sets a ceiling for cash-paying patients by linking US list prices to the lowest developed-nation rates. It functions more as a discount coupon framework than a comprehensive insurance solution for Medicare and privately insured populations.
4. Implications for AstraZeneca
Persistent higher US list prices could increase political scrutiny on AstraZeneca’s pricing practices and affect future negotiations. Pressure from most-favored-nation deals may prompt strategic adjustments to maintain market share and address affordability concerns.